Sinotherapeutics Inc. (SHA:688247)
China
· Delayed Price · Currency is CNY 9.69
-0.05 (-0.51%)
Mar 9, 2026, 4:00 PM EDT
Sinotherapeutics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 446.5 | 511.08 | 299.41 | 246.69 | 314.38 | Upgrade
|
| Other Revenue | - | 0.54 | 0.46 | 0.87 | 1.09 | Upgrade
|
| Revenue | 446.5 | 511.62 | 299.87 | 247.56 | 315.47 | Upgrade
|
| Revenue Growth (YoY) | -12.73% | 70.61% | 21.13% | -21.53% | -1.16% | Upgrade
|
| Cost of Revenue | - | 246.11 | 133.5 | 68.44 | 70.44 | Upgrade
|
| Gross Profit | 446.5 | 265.51 | 166.37 | 179.12 | 245.03 | Upgrade
|
| Selling, General & Admin | - | 55.25 | 43.93 | 43.9 | 45.71 | Upgrade
|
| Research & Development | - | 84.92 | 74.01 | 76.02 | 103.63 | Upgrade
|
| Other Operating Expenses | 391.8 | 2.19 | 3.03 | -0.63 | 0.77 | Upgrade
|
| Operating Expenses | 391.8 | 146.02 | 122.07 | 120.91 | 149.94 | Upgrade
|
| Operating Income | 54.7 | 119.48 | 44.3 | 58.21 | 95.1 | Upgrade
|
| Interest Expense | - | -0 | -0.04 | -0.21 | -0.23 | Upgrade
|
| Interest & Investment Income | - | 16.38 | 17.45 | 25.02 | 5.66 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 2.07 | 1.26 | 5.52 | -4 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.31 | -0.07 | -0.06 | -0.05 | 0.43 | Upgrade
|
| EBT Excluding Unusual Items | 54.38 | 137.86 | 62.91 | 88.48 | 96.95 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.46 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.59 | -0.11 | 0.12 | -0.02 | Upgrade
|
| Asset Writedown | - | -0.92 | -1.62 | -0.85 | -0.1 | Upgrade
|
| Other Unusual Items | - | 5.74 | 4.8 | 9.73 | 51.72 | Upgrade
|
| Pretax Income | 54.38 | 142.08 | 65.99 | 97.48 | 149.01 | Upgrade
|
| Income Tax Expense | 5.44 | 14.38 | 4.92 | 4.54 | 14.1 | Upgrade
|
| Net Income | 48.95 | 127.7 | 61.07 | 92.93 | 134.92 | Upgrade
|
| Net Income to Common | 48.95 | 127.7 | 61.07 | 92.93 | 134.92 | Upgrade
|
| Net Income Growth | -61.67% | 109.09% | -34.28% | -31.12% | 9.42% | Upgrade
|
| Shares Outstanding (Basic) | 445 | 456 | 470 | 422 | 409 | Upgrade
|
| Shares Outstanding (Diluted) | 445 | 456 | 470 | 422 | 409 | Upgrade
|
| Shares Change (YoY) | -2.44% | -2.92% | 11.22% | 3.32% | 0.21% | Upgrade
|
| EPS (Basic) | 0.11 | 0.28 | 0.13 | 0.22 | 0.33 | Upgrade
|
| EPS (Diluted) | 0.11 | 0.28 | 0.13 | 0.22 | 0.33 | Upgrade
|
| EPS Growth | -60.71% | 115.39% | -40.91% | -33.33% | 10.00% | Upgrade
|
| Free Cash Flow | - | 35.3 | -26 | -103.15 | 129.77 | Upgrade
|
| Free Cash Flow Per Share | - | 0.08 | -0.06 | -0.24 | 0.32 | Upgrade
|
| Dividend Per Share | - | 0.062 | 0.041 | 0.062 | - | Upgrade
|
| Dividend Growth | - | 51.22% | -33.87% | - | - | Upgrade
|
| Gross Margin | 100.00% | 51.90% | 55.48% | 72.35% | 77.67% | Upgrade
|
| Operating Margin | 12.25% | 23.35% | 14.77% | 23.51% | 30.14% | Upgrade
|
| Profit Margin | 10.96% | 24.96% | 20.37% | 37.54% | 42.77% | Upgrade
|
| Free Cash Flow Margin | - | 6.90% | -8.67% | -41.67% | 41.13% | Upgrade
|
| EBITDA | 73 | 137.79 | 67.38 | 83.75 | 121.21 | Upgrade
|
| EBITDA Margin | 16.35% | 26.93% | 22.47% | 33.83% | 38.42% | Upgrade
|
| D&A For EBITDA | 18.3 | 18.3 | 23.08 | 25.55 | 26.12 | Upgrade
|
| EBIT | 54.7 | 119.48 | 44.3 | 58.21 | 95.1 | Upgrade
|
| EBIT Margin | 12.25% | 23.35% | 14.77% | 23.51% | 30.14% | Upgrade
|
| Effective Tax Rate | 10.00% | 10.12% | 7.45% | 4.66% | 9.46% | Upgrade
|
| Revenue as Reported | - | 511.62 | 299.87 | 247.56 | 315.47 | Upgrade
|
| Advertising Expenses | - | 0.77 | 0.42 | 0.69 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.